To include your compound in the COVID-19 Resource Center, submit it here.

Starting rare

How Inozyme plans to deploy $49 million series A for rare and chronic diseases

Inozyme Pharma Inc. plans to use its $49 million series A round to demonstrate human proof of concept for its lead candidate in a pair of rare calcification disorders. But the newco and its lead investor Longitude Capital are also

Read the full 402 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers